Omega-3 and Zinc supplementation as complementary therapies in children with attention-deficit/hyperactivity disorder

Area of Science:

• Pediatric Neurology
• Nutritional Psychiatry
• Clinical Pharmacology

Background:

• Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children.
• Standard treatments for ADHD include stimulant medications, but adjunctive therapies are being explored.
• Micronutrients like zinc and omega-3 fatty acids play crucial roles in brain function and development.

Purpose of the Study:

• To assess the efficacy of zinc and omega-3 fatty acid supplementation as adjuncts to standard ADHD treatment in children.
• To compare the effects of zinc, omega-3, and placebo on ADHD symptom severity.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 150 children (6-15 years) diagnosed with ADHD.
• Participants received methylphenidate plus either zinc sulfate, omega-3, or placebo for 8 weeks.
• Symptom severity was measured using Conners' Parent and Teacher Rating Scales at baseline and at weeks 2, 4, and 8.

Main Results:

• Zinc supplementation significantly improved attention-deficit symptoms compared to placebo (P = 0.02).
• Omega-3 supplementation demonstrated superior clinical improvement in ADHD symptoms compared to both zinc and placebo groups (P < 0.05).
• No significant difference was observed between the omega-3 and placebo groups in overall Conners' scale scores (P = 0.89).

Conclusions:

• Zinc supplementation, when used with standard ADHD treatment, can significantly improve attention-deficit symptoms.
• Omega-3 fatty acids appear to be more effective than zinc and placebo in enhancing the clinical management of ADHD symptoms.
• Further research is warranted to elucidate the mechanisms and optimal use of these supplements in pediatric ADHD.